-
Head & Neck Mar 2019Surgery of tongue tumors includes different procedures ranging from mucosal resection to complex combined resection. Numerous terms have been used to describe such...
BACKGROUND
Surgery of tongue tumors includes different procedures ranging from mucosal resection to complex combined resection. Numerous terms have been used to describe such procedures, but there is no consensus between the terminology and the extent of resection.
METHODS AND RESULTS
We searched the medical literature and found a lack of published information. We undertook to describe a new classification of surgical procedures for tongue tumor resection. We based it upon the surgical anatomy of the tongue and the spread of the cancer. We posited that there were five major types of glossectomy embracing all the methods of tongue cancer resection. This classification was reviewed and endorsed by an international team of experts.
CONCLUSION
We propose a more precise classification than that currently in practice, thereby bringing clarity and consistency to the terminology, facilitating shared communication between surgeons, comparison between published research, and ultimately improving surgical practice and patient care.
Topics: Glossectomy; Humans; Tongue Neoplasms
PubMed: 30600861
DOI: 10.1002/hed.25466 -
Acta Biochimica Et Biophysica Sinica Jul 2021Pre-mRNA processing factor 19 (PRPF19) is a multifaceted protein and participates in DNA damage response and pre-mRNA processing. The role of PRPF19 in cancer is...
Pre-mRNA processing factor 19 (PRPF19) is a multifaceted protein and participates in DNA damage response and pre-mRNA processing. The role of PRPF19 in cancer is unclear. Here, we report that the expression of PRPF19 in human tongue cancer is associated with unfavorable prognosis. Overexpression of PRPF19 promotes while knockdown of PRPF19 inhibits tongue cancer cell migration, proliferation, and tumor growth. Overexpression of PRPF19 increases the resistance of tongue cancer cells to radiation and cisplatin treatment. Furthermore, PRPF19 regulates the expression of solute carrier family 40 member 1 (SLC40A1) and mono-ADP ribosylhydrolase 2 (MACROD2), knockdown of SLC40A1 or MACROD2 decreases the sensitivity of tongue cancer cells to radiation and cisplatin treatment. Thus, our results establish a key role of PRPF19 in tongue cancer growth and chemoradiotherapy resistance, targeting PRPF19 would be an effective therapeutic strategy for tongue cancer, especially for those resistant to chemoradiotherapy.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemoradiotherapy; Cisplatin; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Proteins; Nuclear Proteins; RNA Splicing Factors; Radiation Tolerance; Radiation, Ionizing; Tongue Neoplasms; Xenograft Model Antitumor Assays
PubMed: 33954334
DOI: 10.1093/abbs/gmab059 -
Journal of Cancer Research and... Jan 2018Tongue cancer is one of the most common and deadly types of head and neck cancer. The incidence of tongue cancer has been particularly high and remained been increasing... (Review)
Review
Tongue cancer is one of the most common and deadly types of head and neck cancer. The incidence of tongue cancer has been particularly high and remained been increasing in some countries. A main reason for poor prognosis and clinical outcome for tongue cancer was its resistance to chemotherapies, behind which the mechanisms have been not clear. In this review, we summarized literatures published in recent years and listed the proteins, biomacromolecules, and signaling pathways related to this drug resistance. We hoped that this summary could provide reference for researchers to develop new treatment strategies for tongue cancer.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Tongue Neoplasms
PubMed: 29516950
DOI: 10.4103/jcrt.JCRT_763_17 -
Frontiers in Bioscience (Landmark... Jan 2015The differential diagnosis of benign and malignant tongue tumors is crucial to treatment and prognosis. Magnetic resonance imaging (MRI) is the preferred modality for... (Review)
Review
The differential diagnosis of benign and malignant tongue tumors is crucial to treatment and prognosis. Magnetic resonance imaging (MRI) is the preferred modality for the evaluation of tongue carcinomas. Dynamic contrast-enhanced (DCE)-MRI can reflect the density, integrity, and leakiness of tumor vasculature, and the time-intensity curve (TIC) patterns derived from DCE-MRI results can differentiate benign from malignant tumors based on differences in vascular structure. Diffusion-weighted (DW)-MRI is based on the random thermal motion of water molecules and can provide information on the cellular and tissue microstructure of the tumor. A low apparent diffusion coefficient (ADC) derived from DW-MRIs may indicate a malignant tumor. Thus, ADC values and TIC parameters yield complementary information on tumors that may improve diagnostic accuracy. Indeed, the combination of DCE-MRI and DW-MRI is a comprehensive reflection of the pathological status of the tongue tumor, so utilization of these MRI modalities may facilitate the diagnostic differentiation of benign from malignant tumors of the tongue.
Topics: Contrast Media; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Tongue Neoplasms
PubMed: 25553468
DOI: 10.2741/4326 -
Journal of Cellular and Molecular... Jan 2016Tongue squamous cell carcinoma (TSCC) is the most common type of oral squamous cell carcinomas and is well known for its high rate of lymph nodal metastasis. Despite the... (Review)
Review
Tongue squamous cell carcinoma (TSCC) is the most common type of oral squamous cell carcinomas and is well known for its high rate of lymph nodal metastasis. Despite the identification of many molecular mechanisms in TSCC, the number of deaths associated with TSCC increased during the past 5 years. MicroRNAs (miRNAs) are a family of small non-coding RNA molecules, which regulate gene expression by either translational inhibition or mRNA degradation. miRNAs have been proven to be key regulators of various biological and pathological processes including cell proliferation, development and tumourigenesis. Increasing evidence has demonstrated that the deregulated miRNAs are implicated in the diagnosis and treatment of TSCC. In this review, we summarized the expressions and roles of miRNAs in TSCC and comment on the potential roles of miRNAs in diagnosis, prognosis and treatment of this malignancy.
Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; MicroRNAs; Prognosis; RNA Interference; Tongue Neoplasms
PubMed: 26498914
DOI: 10.1111/jcmm.12650 -
Viruses May 2021The incidence of Human-papillomavirus-positive (HPV) tonsillar and base-of-tongue squamous cell carcinoma (TSCC and BOTSCC, respectively) is increasing epidemically, but... (Review)
Review
The incidence of Human-papillomavirus-positive (HPV) tonsillar and base-of-tongue squamous cell carcinoma (TSCC and BOTSCC, respectively) is increasing epidemically, but they have better prognosis than equivalent HPV-negative (HPV) cancers, with roughly 80% vs. 50% 3-year disease-free survival, respectively. The majority of HPV TSCC and BOTSCC patients therefore most likely do not require the intensified chemoradiotherapy given today to head and neck cancer patients and would with de-escalated therapy avoid several severe side effects. Moreover, for those with poor prognosis, survival has not improved, so better-tailored alternatives are urgently needed. In line with refined personalized medicine, recent studies have focused on identifying predictive markers and driver cancer genes useful for better stratifying patient treatment as well as for targeted therapy. This review presents some of these endeavors and briefly describes some recent experimental progress and some clinical trials with targeted therapy.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cell Transformation, Viral; Gene Expression; Humans; Immunohistochemistry; Molecular Targeted Therapy; Mutation; Oncogenes; Papillomavirus Infections; Prognosis; Protein Kinase Inhibitors; Tongue Neoplasms; Tonsillar Neoplasms; Treatment Outcome
PubMed: 34069114
DOI: 10.3390/v13050910 -
Swiss Dental Journal 2017
Topics: Granular Cell Tumor; Humans; Prognosis; Tongue; Tongue Neoplasms
PubMed: 28480946
DOI: No ID Found -
Journal of Ayub Medical College,... 2018
Topics: Child; Female; Humans; Lymphangioma; Tongue; Tongue Neoplasms
PubMed: 29504356
DOI: No ID Found -
Cancer Reports (Hoboken, N.J.) Feb 2022To assess the feasibility of tongue conservation treatment with induction chemotherapy (ICT), tongue conservation surgery, and risk-adapted postoperative adjuvant...
BACKGROUND
To assess the feasibility of tongue conservation treatment with induction chemotherapy (ICT), tongue conservation surgery, and risk-adapted postoperative adjuvant therapy in oral tongue squamous cell carcinoma (OTSCC).
METHODS
Patients with newly diagnosed OTSCC cT2-4 N0-2 M0 were recruited. The ICT with a regimen of docetaxel, cisplatin, and oral tegafur/uracil (DCU) was administrated every 21 days. After the first cycle of ICT (DCU1), patients with a more than 30% decrease in the longest diameter of primary tumor underwent a second cycle of ICT (DCU2). Tongue conservation surgery was performed after ICT, and risk-adapted adjuvant therapy was organized based on pathological features.
RESULTS
From July 2011 to December 2015, a total of 23 patients were enrolled, 87% of whom were classified as stage III-IV. Clinical responders to DCU1 and DCU2 were determined in 90.5% (19/21) and 88.2% (15/17) of patients. Tongue conservation surgery was performed in 16 responders to ICT. Only one patient had a positive margin (6.3%), and a complete pathologic response was achieved in eight patients (50%). Only one patient developed local recurrence after a median follow-up of 58.6 months (range, 7.9-105.2). The 5-year overall survival (0% vs. 87.5%, P = 0.001) and disease-specific survival (0% vs. 93.3%, P = 0.000) were significantly different between the DCU1 nonresponders and responders.
CONCLUSION
Tongue conservation treatment with ICT, followed by conservation surgery and risk-adapted adjuvant therapy, is feasible for patients with OTSCC who are good responders to ICT. However, the outcomes of nonresponders are dismal. Further study in a larger patient population is warranted.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Oral Surgical Procedures; Survival Rate; Tongue Neoplasms
PubMed: 34051137
DOI: 10.1002/cnr2.1456 -
CMAJ : Canadian Medical Association... Jan 2021
Topics: Adolescent; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Neurilemmoma; Tongue; Tongue Neoplasms
PubMed: 33462146
DOI: 10.1503/cmaj.201039